The Medical News

The Medical News

Using PROTACs for targeted protein degradation in drug discovery AMSBIO cfPure ® kits use silica-coated paramagnetic particles to purify cell free DNA from less than 1 mL to greater than 10 mL of serum or plasma. The buffers were developed to ensure efficient recovery of 100 bp – 500 bp DNA fragments in order to maximize recovery of cell free DNA. The recovered DNA is suitable for a wide range of down-stream applications, such as bisulfite sequencing, NGS, and qPCR. The cfPure ® protocol is rapid and easy, allowing users to process several samples in an hour or less and making it ideal for biomarker screening. Using proprietary silica-coated magnetic bead technology, cfPure ® kits are able to efficiently recover low molecular weight cell free DNA during isolation - a key success factor for successful analysis of cfDNA. Designed for scalability, cfPure® kits enable you to use just the number of beads and amount of reagent that you need for your cfDNA extraction. This also means that the number of extractions per kit is dependent on the amount of sample you wish to purify DNA from. In addition to being easy to perform, scalable and easy to automate, cfPure® kits allow you to use less magnetic bead solution if you are purifying small amounts of plasma – saving you money. Since cfDNA is typically found at very low concentrations and in a fragmented state, very efficient DNA capture, as provided by AMSBIO's cfPure™ Cell Free DNA Purification Kits, is vital to provide sensitive and reliable results. Source:



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More